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ABSTRACT
Background: Data on the epidemiology of hepatitis B and C in Bosnia and Herzegovina 
(B&H) are lacking.
Objectives: To assess the prevalence of hepatitis B surface antigen (HBsAg) and anti-hep-
atitis C virus (anti-HCV) in blood samples of first time blood donors in a well-defined 
region of B&H. Our secondary goal was to estimate the prevalence of HBsAg and anti-
HCV in the general population of the same region.
Patients and Methods: We evaluated 8196 blood samples for the presence of HBsAg and/
or anti-HCV, adjusted for differences in gender, and used the ratio estimation method 
to determine the prevalence in the general population.
Results: We analyzed 1263 (15.4%) female and 6933 (84.6%) male blood donors (male-to-
female ratio: 5.49 to 1). The adjusted prevalence of HBsAg among blood donors was 
0.787% (95% CI = 0.535-1.038), while the prevalence of anti-HCV was 0.267% (95% CI = 
0.016-0.519). There was no difference in the prevalence of HBsAg or anti-HCV between 
men and women. We estimate that the prevalence of HBsAg and anti-HCV in the gen-
eral population is 1.057% to 1.535% and 0.29% to 0.89%, respectively.
Conclusions: The prevalence of HBsAg and anti-HCV among blood donors suggests that 
our region has low endemicity for both hepatitis B and hepatitis C.
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1. Background
Viral hepatitis B and hepatitis C are significant global 
health issues for industrialized and developing coun-
tries. It is estimated that there are 2 billion people who 
have been exposed to hepatitis B worldwide, with 350 
million suffering from chronic infection (1). The statis-
tics for hepatitis C are hardly better – it is estimated that 
there are more than 200 million people who are chroni-
cally infected throughout the world (2). Hepatitis B is es-
timated to result in 563,000 deaths annually versus 366 
000 deaths for hepatitis C (3). Data on the epidemiology 
of hepatitis B and C in Bosnia and Herzegovina (B&H) are Hepat Mon. 2011;11(8):629-633
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sparse. There are some reports of the prevalence of hepa-
titis B among smaller groups of first time blood donors 
and the prevalence of hepatitis C in special groups of pa-
tients (4-7). However, there are no accurate data regard-
ing the numbers of those who have been exposed and 
chronically infected in the general population in B&H.
2. Objectives 
We aimed to assess the prevalence of hepatitis B sur-
face antigen (HBsAg) and anti-hepatitis C virus (anti-
HCV) in blood samples of all first time blood donors who 
resided in a very well-defined region of northeast B&H in 
2009. Our secondary goal was to estimate the prevalence 
of HBsAg and anti-HCV in the general population of this 
region.
3. Patients and Methods
3.1. Settings
Since the end of the Bosnian War (1992-1995), Bosnia 
and Herzegovina has comprised 2 entities – the Federa-
tion of Bosnia and Herzegovina and the Republic of Srp-
ska. The Federation of Bosnia and Herzegovina consists 
of 10 cantons, one of which is the Tuzla Canton, a well-de-
fined region in the northeast of Bosnia and Herzegovina. 
The estimated population in the region, as of December 
31, 2010, is 496,280 (Federal Office of Statistics, Federation 
of Bosnia and Herzegovina, Sarajevo). University Clinical 
Center Tuzla is a regional hospital center that serves as 
a secondary and tertiary referral center for the region. 
Blood donation in B&H is exclusively voluntary, without 
the possibility of financial compensation for donations.
3.2. Patients and Methods
In 2009 (January 1st to December 31st, 2009), we evaluat-
ed approximately 10,000 voluntary blood donors at the 
Department of Transfusion Medicine in University Clini-
cal Center Tuzla (Tuzla, B&H). All volunteers were obliged 
to satisfy the hospital’s criteria, which included: age over 
18 and less than 65, body weight over 50 kg, normal body 
temperature, absence of clinical signs of an acute infec-
tive response, normal systolic and diastolic blood pres-
sure, normal pulse and respiration rate, and absence 
of serious chronic condition (eg, chronic heart failure, 
diabetes mellitus with complications). Inclusion criteria 
were first time blood donations and place of residence in 
the Tuzla Canton.
Ultimately, we analyzed 8196 blood samples from the 
same number of blood donors, which represents 1.651% 
of the population of Tuzla Canton. We also recorded the 
age and gender of each blood donor. All blood samples 
were  routinely  screened  for  transfusion-transmitted 
diseases per established screening procedures and tests. 
Therefore, all blood samples were tested for HBsAg and 
anti-HCV by chemiluminescent microparticle immu-
noassay (CMIA) on the Architect i2000 system (Abbott 
Laboratories,  USA).  Every  sample  that  was  positive  in 
the initial screen was retested to confirm seropositivity. 
Markers of exposure to hepatitis B (anti-HBsAg and anti-
HBcAg) are not routinely measured in our blood bank. 
The study protocol was approved by the University Clini-
cal Center Tuzla Ethical Committee.
3.3. Statistical Analysis
All tests were performed using SPSS 15.0 (SPSS Inc, USA) 
and  Excel  2007  (Microsoft,  USA).  Descriptive  statistics 
were used to determine the baseline characteristics. We 
used student’s t-test to compare quantitative variables 
and chi-square test to compare categorical variables. 
The prevalence of seropositivity for HBsAg and anti-
HCV in blood donors was expressed as the percentage 
of  seropositive  samples.  We  corrected  for  differences 
in gender (predominantly males in the sample) per a 
standard method (8, 9). The prevalence of seropositiv-
ity for HBsAg and anti-HCV was standardized based on 
the yearly (December 31, 2009) population estimates in 
our region from the Federal Office of Statistics (Federa-
tion of Bosnia and Herzegovina, Sarajevo). Gender-stan-
dardized  incidence  rates  were  calculated  using  popu-
lation weights for Tuzla Canton in the age group 18-65 
years (Males: 48.9325; Females: 51.0674). 95% confidence 
intervals (95% CI) of prevalence rates were estimated as-
suming a Poisson distribution of the cases. We used the 
ratio estimation method to estimate the prevalence of 
HBsAg and anti-HCV in the general population, as used 
for the prevalence of cocaine use (10). The method entails 
a calculation of the ratio between known prevalences 
in 2 populations (i.e. blood donors and general popula-
tion). This ratio is then used to estimate the prevalence 
in a population, based on the knowledge of prevalence 
in another population (i.e. calculating the prevalence in 
a general population based on the prevalence in blood 
donors).  We  reviewed  several  studies  from  countries 
with data on the prevalence of hepatitis B and hepatitis 
C in general population and blood donors, and using the 
ratio estimation method, we calculated estimated the 
prevalence of HBsAg and anti-HCV in general population 
in Tuzla Canton. A statistical level of 95% (P < 0.05) was 
considered significant for all tests.
4. Results
We  analyzed  8196  blood  samples  from  6933  (84.6%) 
male blood donors. The male-to-female ratio was 5.49 to 
1. The mean age ± SD in the entire sample was 36.69 ± 12.21 
years, ranging from 18 to 69 years. Male blood donors 
(37.43 ± 11.81 years) were aged an average of 4.81 older 
(95% CI = 4.09-5.53) than female donors (32.63 ± 13.49) (t = 
13.009; df = 8194; P < 0.001). The distribution of ages and 
genders is shown in Figure 1.
4.1. Prevalence of HBsAg Among Blood Donors
We  identified  74/8196  HBsAg-seropositive  samples, 
which corresponded to a crude prevalence of 0.903% (95% Hepat Mon. 2011;11(8):629-633
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CI = 0.7-1.1). There were 66/6963 HBsAg-positive samples 
among men, consistent with a crude prevalence of 0.947% 
(95% CI = 0.72-1.18). We detected 8/1263 HBsAg-seropositive 
samples among female blood donors, corresponding to 
a crude prevalence of 0.633 (95% CI = 0.19-1.07). There was 
no significant difference in the frequency of HBsAg sero-
positivity between males and females (X2 = 1.186; df = 1; P 
= 0.35). After standardizing by population weights of Tu-
zla Canton, the corrected and standardized prevalence of 
the entire sample was 0.787% (95% CI = 0.535-1.038). The 
percentages of HBsAg-seropositive samples by age and 
gender are presented in Figure 2.
4.2. Prevalence of Anti-HCV Among Blood Donors
We detected 19/8196 anti-HCV-seropositive blood sam-
ples, equivalent to a crude prevalence of 0.232% (95% CI 
= 0.13-0.33). Among men, we detected 15/6963 anti-HCV 
seropositive cases and 4/1263 such cases among women, 
which corresponded to a crude prevalence of 0.215% (95% 
CI = 0.11-0.33) and 0.317% (95% CI = 0.01-0.63), respectively. 
This difference in ratio of anti-HCV seropositive blood 
samples between male and female blood donors was not 
significant (X2 = 0.476; df = 1; P = 0.71). After standardiza-
tion  and  correction,  we  calculated  a  corrected  preva-
lence of 0.267% (95% CI = 0.016-0.519). The percentage of 
anti-HCV seropositive samples by age and gender is pre-
sented in Figure 3.
4.3. Estimated Prevalence of HBsAg and Anti-HCV Seropositiv-
ity within the general population of Tuzla Canton
Using the ratio estimation method described above, 
we assessed the prevalence of HBsAg and anti-HCV sero-
positivity within the general population of Tuzla Canton. 
The reported prevalence of HBsAg among blood donors 
and the general population in various countries is pre-
sented in Table 1. We calculated the ratio between the 
prevalence of HBsAg in the general population and that 
in blood donors for each country. As seen in Table 1, the 
ratios ranged from 1.17 to 1.70. Based on these ratios and 
according to our calculated prevalence among blood do-
nors, we estimated a prevalence of HBsAg in the general 
population of Tuzla Canton of 1.057% to 1.535%. Similarly, 
we calculated the ratios of the prevalence of anti-HCV se-
ropositivity between the general population and blood 
donors by country. As seen in Table 1, the ratios ranged 
from 1.25 to 3.85. Based on these ratios and according to 
our calculated prevalence among blood donors, we esti-
mated a prevalence of anti-HCV in the general popula-
tion of Tuzla Canton of 0.29% to 0.89%.
5. Discussion
Data on the epidemiology of hepatitis B and C in B&H 
are lacking. Prior to 2007, the prevalence of hepatitis B in 
the general population in B&H was estimated by extrap-
olating the prevalence in neighboring countries. Hence, 
it was proposed that B&H belonged to a region of inter-
mediate endemicity. In 2007, our group investigated 716 
first time blood donors in a separate study, calculating a 
prevalence of HBsAg positivity of 3.6% (7). However, this 
figure must be considered cautiously, due to the small 
sample. Additionally, we recruited all persons who do-
nated blood during a single month, regardless of their 
place of residence. The prevalence of HBsAg among blood 
Country Study Report
Prevalence Among 
Blood Donors, %
Prevalence Among 
General Population, %
Ratio
HBsAg seropositivity
England Soldan K et al., 2003 (17)
Gay NJ et al., 1999 (18)
0.316
-
-
0.37
1.17
India Bhattacharya P et al., 2007 (19)
Batham A et al., 2007 (20)
1.66
-
-
2.4
1.45
Greece 
(Crete)
Koulentaki M et al., 1999 (21) 0.401 0.6 1.5
Albania Durro V et al., 2010 (22)
Kondili LA et al., 2007 (23)
6.7
-
-
8.1 1.21
Croatia Grgicevic D et al., 2000 (11) 0.341 0.4 1.17
Turkey Acar A et al., 2010 (24)
Pirnar A et al., 1976 (25)
1.76
-
-
3
1.70
Anti-HCV seropositivity
England Soldan K et al., 2003 (17) 0.16 0.2 1.25
India Bhattacharya P et al., 2007 (19) 0.35 0.87 2.49
Greece Koulentaki M et al., 1999 (21)
Goritsas C et al., 2000 (10)
0.382
-
-
1.25
3.27
Croatia Grgicevic D et al., 2000 (11) 0.26 1 3.85
Table 1. Ratios of Country Prevalence of HBsAg and Anti-HCV Seropositivity in General Population and Blood DonorsHepat Mon. 2011;11(8):629-633
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donors of 0.787% presenting the current study is more re-
liable and, as seen in Table 1, is much closer to the figures 
in Croatia, a similar, neighboring country (11). We were 
not able to determine the prevalence of HBsAg among 
blood donors in Serbia (another neighboring country), 
although the recently separated, underdeveloped region 
of Kosovo has a significantly higher prevalence of 4.2% 
(12).  The  number  of  hepatitis  B-exposed  blood  donors 
should be evaluated, but our Department of Transfusi-
ology does not routinely screen blood for anti-HBsAg or 
anti-HBcAg. This practice must be changed due to the 
small but realistic danger of occult hepatitis B infection 
in HBsAg-negative blood donors (13, 14).
Epidemiological reports on hepatitis C prevalence in 
B&H have dealt primarily with either special or high-risk 
groups (4, 5). A report from 2006 used a smaller sample 
of 2000 blood donors as a control group and reported an 
anti-HCV prevalence of 0.2% (5). We  calculated a preva-
lence of 0.267%, similar the 0.26% rate reported in Croatia 
(11). Additionally, a study from Kosovo reported a simi-
lar prevalence of anti-HCV of 0.3% in blood donors (12). 
Epidemiological studies of blood donors are frequently 
used as a surrogate for general population studies on the 
epidemiology of hepatitis B and C, because an epidemio-
logical assessment of general population is difficult to 
perform due to the required sample size and recruitment 
problems. Financial requirements for a survey of such 
magnitude are another obstacle. On the other hand, do-
nors willingly donate their blood, which is routinely and 
conveniently screened for hepatitis B and C, allowing for 
quick sample collection and analysis. Yet, the estimated 
prevalence of hepatitis B and C in blood donors is nearly 
always below the actual prevalence in the general popu-
lation. Blood donors, especially volunteer blood donors, 
are usually a healthier segment of population and are ac-
tively screened prior to donation, which may be reasons 
for the lower rates. Many countries either conduct na-
tionwide epidemiological surveys (fortunate countries) 
or combine several regional surveys (less fortunate coun-
tries) and extrapolate the overall prevalence, or they do 
not conduct any surveys on the general population at all; 
some nations investigate populations that are regularly 
screened and are close to the general population, such 
as blood donors (the least fortunate countries). However, 
the estimated prevalence of a general population is rare-
ly (if ever) based on a particular method of calculation—
it is based primarily on speculation. Our study is an at-
tempt to use an established method in a new field and 
avoid guesswork.
In situations in which it is not easy to perform a popu-
lation-based study, the ratio estimation method can be 
used cautiously to estimate prevalence; this method has 
been successfully used to determine the prevalence of 
cocaine use in a situation in which it was not possible to 
conduct a field study (15). We used the same method to 
calculate the ratios of prevalence of HBsAg and anti-HCV 
in the general population and blood donors in several 
countries. The estimated prevalence of HBsAg seroposi-
tivity in the general population in our area of B&H was 1% 
to 1.5%, suggesting that our country belongs to a group of 
nations with low endemicity for hepatitis B. With regard 
to hepatitis C, the estimated prevalence of anti-HCV in 
the general population of our region ranges from 0.3% to 
0.9%, possibly toward the lower end. These values reflect 
Figure 1. Distribution of the First Time Blood Donors According to Age And 
Gender
Figure 2. Distribution of HBsAg Seropositivity Among First Time Blood 
Donors According to Age and Gender
Tuzla Canton. Bosnia and Herzegovina. year 2009
Tuzla Canton. Bosnia and Herzegovina. year 2009
Figure 3. Distribution of Anti-HCV Seropositivity Among First Time 
Blood Donors According to Age and Gender
Tuzla Canton. Bosnia and Herzegovina. year 2009Hepat Mon. 2011;11(8):629-633
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a region with a lower prevalence of hepatitis C and are 
similar to those in reports on surrounding countries. In 
support of our estimate, a study calculated a 0.4% preva-
lence of anti-HCV among 1699 health care workers (5), a 
well-established risk group with a minor to modest risk 
for hepatitis C (16).
These numbers must be cautiously interpreted, be-
cause they are merely an estimate and do not substitute 
for a real assessment. Vaccination programs against HBV 
have existed in our country since 2001, but those born 
before 2001 are infrequently vaccinated. As noted, blood 
donors are usually healthier segments of a population 
and probably less prone to risky behaviors and lifestyles 
that lead to hepatitis infection. Moreover, blood donors 
are aged 18 to 65, rendering a substantial proportion of 
the population uninvestigated. These are merely some 
of the potential confounders that need to be taken into 
account. Nevertheless, until there is a population-based 
survey, this is currently the best estimate. We are, how-
ever, convinced that true prevalence lies within the in-
tervals above. The study would have been more reliable 
if we had included more blood donors – possibly over 2 
or 3 years. Yet, such a change would not have affected the 
prevalence, because we evaluated 1.65% of the general 
population in our region. 
In conclusion, the prevalence of HBsAg and anti-HCV 
among blood donors suggests that our region has low 
endemicity for hepatitis B and hepatitis C. Accurate epi-
demiological surveys must be performed to determine 
the true prevalence of hepatitidem in the general popu-
lation.
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